Could this be another SGX fairy-tale in the making, resembling the supersonic rallies of AEM Holdings and iFAST Corporation? Within a year, iX Biopharma share price had rocketed by an eye-popping 2,400%, surging from $0.020 to a high of $0.52.  In light of the explosive form of iX Biopharma share price, an SG Wealth Builder member has requested for my insights. By way of background, iX Biopharma Ltd is a specialty pharmaceutical and nutraceutical company focused on drug development and manufacturing. The company’s core technology lies in its flagship, patent-protected WaferiX® sublingual drug-delivery platform. This base platform patent holds significant strategic value, enabling iX Biopharma to secure numerous product-specific patents—including Wafermine®, Wafesil®, and the MeltMed Series. To be frank, I think few investors would have paid attention to iX Biopharma prior to the historic rally. And for good reasons too. Listed in Catalist only in 2015, iX Biopharma had never been profitable and had been racking in multi-million losses year in and...